CIGB 50

Drug Profile

CIGB 50

Alternative Names: Anti-IL-15-vaccine-CIGB; Anti-interleukin-15-vaccine-CIGB; CIGB50

Latest Information Update: 24 Feb 2016

Price : $50

At a glance

  • Originator Center for Genetic Engineering and Biotechnology; Heber Biotec
  • Class Vaccines
  • Mechanism of Action Advanced glycosylation end product modulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Rheumatoid arthritis

Most Recent Events

  • 24 Feb 2016 Phase-I clinical trials in Rheumatoid arthritis in Cuba (SC) prior to February 2016 (CIGB-Heber Biotech pipeline, February 2016)
  • 31 Dec 2015 Immunogenicity data from a preclinical trial released by CIGB (CIGB-Heber Biotech presentation, 2014-2015)
  • 31 Dec 2013 Preclinical trials in Rheumatoid arthritis in Cuba (SC) (CIGB presentation,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top